Bioxyne was hit with an impairment charge of A$11.5 million in the first half of FY24 […]
Half-Year and Full-Year Financial Results: Bioxyne, Rua Bioscience, Bod Science, Avecho, Wellnex Life, MGC Pharma, Cannasouth
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
Avecho Biotechnology
Bioxyne
Bod Science
Breathe Life Sciences
George Karafotias
Rua Bioscience
Sam Watson
Wellnex Life
Zalm Therapeutics